Showing 279 results for "chronic thromboembolic pulmonary hypertension"

Balloon Angioplasty Seen to Benefit People with Inoperable CTEPH and Other Conditions, Too

Balloon pulmonary angioplasty (BPA) appears to be of multiple benefit to patients with chronic thromboembolic pulmonary hypertension (CTEPH), both in terms of hemodynamics and in other systemic disorders like glycemic control and kidney disease, according to a study published in the journal Circulation, titled “Multiple Beneficial Effects of Balloon Pulmonary Angioplasty in Patients…

CTEPH: What You Need to Know

https://www.youtube.com/watch?v=W2YLo6U1uFU Pulmonary hypertension (PH)  is a rare lung disease that refers to an increase in blood pressure in the pulmonary arteries. Unfortunately, there is still no known cure available to end PH, but research has been evolving and doctors and scientists have been discovering some new ways to approach this…

Hemodynamic Exercise Response of PH Patients Seen to Predict Transplant-free Survival Chances

Pulmonary hemodynamic response to exercise can predict the transplant-free survival chances of people with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), according to researchers at the University Hospital Zurich, Switzerland, studying the mean pulmonary arterial pressure to cardiac output (mPAP/CO) relationship during exercise in these patients. The research, titled “Pressure-flow during…

Gabriele’s CTEPH Story: #BreathOfSuccess

When Gabriele from Verona, Italy, was diagnosed with chronic thromboembolic pulmonary hypertension (known as “CTEPH”), he was living a very active life. His doctors told him that surgery might restore his health. Today, he is able to play basketball again and even coaches a sports team for people with…

CTPER-index May Be a Potential CTEPH Diagnostic Tool

Researchers have developed a computer tomography pulmonary embolism residua index (CTPER-index) that may prove to be a useful tool for diagnosis and treatment decisions regarding chronic thromboembolic pulmonary hypertension and dyspnea. The research paper, “Computed tomography pulmonary embolism residua index (CTPER-index): a simple tool for pulmonary embolism residua description,” was…

Likely Prognosis for CTEPH Patient Group Found in 2 Easy to Test Markers

In a new study, researchers determined that elevated serum bilirubin levels and a low 6-minute walk distance are predictors of poor prognosis in patients with inoperable chronic thromboembolic pulmonary hypertension. The research — whose findings appear to offer important disease prognosis markers — is titled “Serum Bilirubin and 6-min Walk Distance as Prognostic Predictors…

PH Awareness Goes High Tech With phaware365 Mobile App

The Burbank, California-based non-profit phaware is a global association dedicated to creating awareness about pulmonary hypertension through engagement and technological innovation to discover and chart the course to a cure. Pulmonary hypertension (PH) is a rare, chronic lung disease that affects the functioning of the heart and can lead to fatal…

CTEPH Patients in Wales Now Have Option of Using Bayer’s Adempas

Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) or recurrent CTEPH in Wales now have access to Bayer’s therapy Adempas (riociguat) — a soluble guanylate cyclase (sGC) stimulator that works by relaxing blood vessels and increasing the supply of blood to the lungs, which helps reduce the workload of the heart. The All Wales Medicines…

Opsumit for PH

Last updated Nov. 14, 2022, by Teresa Carvalho, MS  Fact-checked by José Lopes, PhD What is Opsumit for PH? Opsumit (macitentan), is an oral once-daily therapy used to widen the blood vessels of people with pulmonary arterial hypertension (PAH), slowing disease progression and reducing patients’ risk of being hospitalized.